Comparing Cellular Depletion in B-Cell Therapy for Lupus Patients

The chapter delves into a study contrasting the effectiveness of rituximab and ionolumab in depleting cells, with ionolumab showing substantial cellular depletion by inhibiting B-cell survival. The speaker is hopeful about the promising data of ionolumab for treating lupus patients, foreseeing potential FDA approval in the future.